Zovirax®
acyclovir · oral tablet
Antiviral
Approved uses
Acute herpes zoster, including herpes zoster ophthalmicus
800 mg every 4 hours, 5 times daily, for 7 to 10 days.
Started within 72 hours of rash onset it reduces keratitis and uveitis but not postherpetic neuralgia.
OFF-LABELNot in the FDA label for this product
Long-term suppression of recurrent ocular HSV disease
400 mg twice daily for 12 months.
RCT · n=703
Herpetic Eye Disease Study Acyclovir Prevention Trial, a randomized double-masked placebo-controlled multicenter trial in 703 immunocompetent patients who had had ocular HSV disease within the preceding year: cumulative probability of a recurrence of any type of ocular HSV disease over the 12-month treatment period was 19% on acyclovir versus 32% on placebo (P<0.001), and among the 337 patients with a history of stromal keratitis, recurrent stromal keratitis was 14% versus 28% (P=0.005); nonocular, primarily orofacial, recurrence was also lower at 19% versus 36% (P<0.001), and there was no rebound in the rate of HSV disease in the 6 months after treatment stopped. A further analysis of the same trial gave rate ratios of 0.62 (95% CI 0.39 to 0.97) for preventing epithelial keratitis and 0.57 (95% CI 0.36 to 0.89) for preventing stromal keratitis, with the absolute benefit greatest in patients with the most prior episodes, and the authors report that the benefit in preventing stromal keratitis was seen solely among patients with a history of stromal keratitis.
HSV epithelial (dendritic) keratitis
400 mg 5 times daily.
RCT · n=60 · equal to topical
Randomized double-blind trial in 60 patients with simple dendritic corneal ulceration comparing acyclovir 400 mg tablets 5 times daily against acyclovir ophthalmic ointment 5 times daily: 88.9% healed on the oral drug versus 96.6% on the ointment, a difference that was not significant, with a median healing time of 5 days in both groups and trough tear concentrations within or above the range of mean in vitro ID50 levels for HSV-1. A Cochrane review of 137 studies in 8333 eyes reports that in a limited number of studies oral acyclovir alone (RR 0.92, 95% CI 0.79 to 1.07) or combined with a topical antiviral (RR 1.36, 95% CI 0.68 to 2.74) appeared as effective as a single topical antiviral agent.
HSV stromal keratitis, added to topical corticosteroid plus topical antiviral
400 mg 5 times daily for 10 weeks.
RCT · n=104 · no benefit
Herpetic Eye Disease Study, a randomized double-masked placebo-controlled multicenter trial in 104 patients with HSV stromal keratitis without accompanying epithelial keratitis, all of whom also received topical prednisolone phosphate and trifluridine: median time to treatment failure was 84 days (95% CI 69 to 93) on acyclovir versus 62 days (95% CI 57 to 90) on placebo, and by 16 weeks 75% versus 74% had failed, neither difference significant. The authors concluded there was no statistically or clinically significant beneficial effect on time to treatment failure, proportion failing, proportion resolving, time to resolution, or 6-month best-corrected visual acuity, while also reporting that visual acuity improved over 6 months in more patients on acyclovir than on placebo.
Contraindications
Demonstrated clinically significant hypersensitivity reaction, such as anaphylaxis or a severe cutaneous adverse reaction, to acyclovir, valacyclovir, or any component of the formulation.
400 mg and 800 mg tablets; bottles of 100 and 500 tablets
Synthetic purine nucleoside analogue with in vitro and in vivo inhibitory activity against HSV-1, HSV-2 and varicella-zoster virus (VZV). Thymidine kinase (TK) encoded by HSV and VZV converts acyclovir to acyclovir monophosphate, and cellular enzymes complete conversion to acyclovir triphosphate. In vitro, acyclovir triphosphate stops replication of herpes viral DNA by competitive inhibition of viral DNA polymerase, incorporation into and termination of the growing viral DNA chain, and inactivation of the viral DNA polymerase. The inhibitory activity of acyclovir is highly selective due to its affinity for the viral TK. Most acyclovir-resistant mutants isolated thus far from immunocompromised patients have been TK-deficient. In a review of herpes simplex virus resistance to acyclovir, thymidine kinase deficiency accounts for approximately 95% of acyclovir-resistant isolates.
Warnings & Precautions
- Oral ingestion only: Acyclovir tablets are intended for oral ingestion only.
- Renal failure: Reported with therapy and fatal in some cases; adjust the dose in renal impairment and maintain adequate hydration.
- Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: TTP/HUS, which has resulted in death, has occurred in immunocompromised patients receiving therapy.
- Severe cutaneous adverse reactions: AGEP, DRESS, Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme have been reported; discontinue immediately if a painful rash with mucosal involvement or a progressive severe rash develops, closely monitor clinical status and initiate appropriate therapy. Contraindicated in patients who have developed SCARs with the use of acyclovir or valacyclovir, or any component of the formulation.
- Renal dysfunction: Use caution with potentially nephrotoxic agents, since this may increase the risk of renal dysfunction and/or of reversible central nervous system symptoms such as those reported with intravenous acyclovir.
- Drug interactions: Coadministration of probenecid with intravenous acyclovir has been shown to increase the mean acyclovir half-life and the area under the concentration-time curve, and urinary excretion and renal clearance were correspondingly reduced.
- Geriatric use: Plasma concentrations are higher in geriatric patients, duration of pain after healing was longer in patients 65 and over, and nausea, vomiting, and dizziness were reported more frequently in elderly subjects. Elderly patients are more likely to have reduced renal function and require dose reduction, and are also more likely to have renal or CNS adverse events. Somnolence, hallucinations, confusion and coma observed during clinical practice were reported more frequently in elderly patients.
- Herpes zoster: There are no data on treatment initiated more than 72 hours after onset of the zoster rash; advise patients to initiate treatment as soon as possible after a diagnosis of herpes zoster.
- Genital herpes infections: Acyclovir is not a cure for genital herpes, and there are no data evaluating whether it will prevent transmission to others. Patients should avoid contact with lesions or intercourse when lesions and/or symptoms are present, and genital herpes can also be transmitted through asymptomatic viral shedding. If medical management of a recurrence is indicated, advise patients to initiate therapy at the first sign or symptom of an episode.
- Chickenpox: Treatment was initiated within 24 hours of the typical chickenpox rash in the controlled studies, and there is no information regarding the effects of treatment begun later in the disease course.
Common Side Effects
In clinical trials the most frequent adverse event was malaise (11.5% versus 11.1% on placebo) with 800 mg 5 times daily for herpes zoster, nausea and/or vomiting (2.7% versus 0.7% on placebo) with short-term genital herpes treatment, nausea (4.8%) and diarrhea (2.4%) with 400 mg 2 times daily for 1 year to prevent recurrences, and diarrhea (3.2% versus 2.2% on placebo) in chickenpox. Post-approval events, with frequency unknown, include visual abnormalities; agitation, confusion, hallucinations, seizure, somnolence, coma and other nervous system symptoms, which may be marked, particularly in older adults or in patients with renal impairment; renal failure, elevated creatinine and hematuria; Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS and other skin reactions; anaphylaxis and angioedema; anemia, leukopenia and thrombocytopenia; and hepatitis and jaundice.
Pregnancy: Category B. Not teratogenic in mice, rabbits or rats at plasma levels 9 to 106 times human levels, and a prospective registry of 749 first-trimester systemic exposures yielding 756 outcomes found a birth defect rate approximating the general population, though the registry was too small for reliable or definitive conclusions. There are no adequate and well-controlled studies in pregnant women; use only if the potential benefit justifies the potential risk to the fetus.
Lactation: Breast milk concentrations documented in 2 women ranged from 0.6 to 4.1 times corresponding plasma levels, potentially exposing a nursing infant to up to 0.3 mg/kg/day; administer to a nursing mother with caution and only when indicated.
Safety and effectiveness of oral formulations are not established below 2 years of age.